Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia

for the Kanto Study Group for Cell Therapy (KSGCT)

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7%, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0% (p = .01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.

Original languageEnglish
Pages (from-to)1-6
Number of pages6
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - 2017 Oct 16

Fingerprint

Leukemia, Myelomonocytic, Chronic
Hematopoietic Stem Cell Transplantation
Cytogenetics
Transplantation
Survival
Disease-Free Survival
Transplants

Keywords

  • allogeneic
  • chronic myelomonocytic leukemia
  • Cytogenetics
  • hematopoietic stem transplantation
  • prognosis
  • scoring system

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia. / for the Kanto Study Group for Cell Therapy (KSGCT).

In: Leukemia and Lymphoma, 16.10.2017, p. 1-6.

Research output: Contribution to journalArticle

@article{84f4356a744a447b8ee534a6149848ad,
title = "Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia",
abstract = "Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7{\%}, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0{\%} (p = .01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.",
keywords = "allogeneic, chronic myelomonocytic leukemia, Cytogenetics, hematopoietic stem transplantation, prognosis, scoring system",
author = "{for the Kanto Study Group for Cell Therapy (KSGCT)} and Kenji Motohashi and Shin Fujisawa and Noriko Doki and Takeshi Kobayashi and Takehiko Mori and Kensuke Usuki and Masatsugu Tanaka and Shinichiro Fujiwara and Shinichi Kako and Yasuyuki Aoyama and Masahiro Onoda and Shingo Yano and Moritaka Gotoh and Heiwa Kanamori and Satoshi Takahashi and Shinichiro Okamoto",
year = "2017",
month = "10",
day = "16",
doi = "10.1080/10428194.2017.1387913",
language = "English",
pages = "1--6",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia

AU - for the Kanto Study Group for Cell Therapy (KSGCT)

AU - Motohashi, Kenji

AU - Fujisawa, Shin

AU - Doki, Noriko

AU - Kobayashi, Takeshi

AU - Mori, Takehiko

AU - Usuki, Kensuke

AU - Tanaka, Masatsugu

AU - Fujiwara, Shinichiro

AU - Kako, Shinichi

AU - Aoyama, Yasuyuki

AU - Onoda, Masahiro

AU - Yano, Shingo

AU - Gotoh, Moritaka

AU - Kanamori, Heiwa

AU - Takahashi, Satoshi

AU - Okamoto, Shinichiro

PY - 2017/10/16

Y1 - 2017/10/16

N2 - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7%, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0% (p = .01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.

AB - Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment for chronic myelomonocytic leukemia (CMML); however, factors predicting allo-HSCT outcomes for CMML have not been well defined. This study assessed whether the existing five scoring systems for CMML prognosis could be applied for predicting allo-HSCT outcomes. We retrospectively evaluated 38 patients who underwent allo-HSCT for CMML from 2000 to 2014. At 3 years, overall survival (OS) and disease-free survival were 34.6 and 24.7%, respectively. According to the risk stratification at the time of transplantation, only the CMML-specific cytogenetic risk scoring system could successfully predict transplantation outcomes. At 3 years, OS was 56.7, 12.5, and 0% (p = .01) in the low, intermediate, and high-risk groups. Our data suggest that the CMML-specific cytogenetic risk stratification at transplant may be useful for identifying patients with CMML who may benefit from HSCT. However, further studies are warranted to confirm this observation.

KW - allogeneic

KW - chronic myelomonocytic leukemia

KW - Cytogenetics

KW - hematopoietic stem transplantation

KW - prognosis

KW - scoring system

UR - http://www.scopus.com/inward/record.url?scp=85031490839&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031490839&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1387913

DO - 10.1080/10428194.2017.1387913

M3 - Article

SP - 1

EP - 6

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -